Jove
Visualize
Contáctanos
JoVE
x logofacebook logolinkedin logoyoutube logo
ACERCA DE JoVE
Visión GeneralLiderazgoBlogCentro de Ayuda JoVE
AUTORES
Proceso de PublicaciónConsejo EditorialAlcance y PolíticasRevisión por ParesPreguntas FrecuentesEnviar
BIBLIOTECARIOS
TestimoniosSuscripcionesAccesoRecursosConsejo Asesor de BibliotecasPreguntas Frecuentes
INVESTIGACIÓN
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchivo
EDUCACIÓN
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualCentro de Recursos para ProfesoresSitio de Profesores
Términos y Condiciones de Uso
Política de Privacidad
Políticas

Videos de Conceptos Relacionados

Classification of Skeletal Muscle Relaxants01:28

Classification of Skeletal Muscle Relaxants

Skeletal muscle relaxants are a group of drugs that can reduce muscle stiffness and induce temporary paralysis to relieve pain. These agents can act centrally to reduce muscle tone or spasms in painful conditions such as multiple sclerosis (MS), amyotrophic lateral sclerosis (ALS), or spinal injuries; they are called antispasmodics or spasmolytics.
Peripherally acting skeletal muscle relaxants interfere with the neurotransmission at the neuromuscular end plate to induce paralysis during...
Clearance Models: Physiological Models01:09

Clearance Models: Physiological Models

Drug clearance is a critical pharmacokinetic process involving the irreversible removal of drugs from the body through various organs over a specified time period. Physiological models are indispensable in determining organ-specific clearance, defined by the proportion of the drug eliminated per unit of time from the organ's blood volume.
The organ's clearance rate depends on the blood flow to the organ and the extraction ratio (E). The extraction ratio describes the organ's proficiency in drug...
Clearance Models: Compartment Models01:25

Clearance Models: Compartment Models

Clearance measures drug elimination from the central compartment, including plasma and highly perfused organs like kidneys and liver. Its calculation varies depending on pharmacokinetic models and administration routes. The one-compartment model, for instance, portrays the pharmacokinetics of polar drugs such as aminoglycoside antibiotics administered intravenously and readily excreted in urine. In this case, clearance is influenced by the terminal rate constant (λz) and the total volume of...

También podría leer

Artículos Relacionados

Artículos vinculados a este trabajo por autores compartidos, revista y gráfico de citas.

Ordenar por
Same author

Elimination of myotonia improves myopathy in a muscleblind-like knockout model of myotonic dystrophy.

Nature communications·2026
Same author

A Phase 1 Study of Convection-Enhanced Delivery of Intraputaminal AAV2-GDNF in Advanced Parkinson's Disease.

Movement disorders : official journal of the Movement Disorder Society·2026
Same author

AAV-Delivered RNAi Targeting Mutant LDB3 Prevents and Reverses Myofibrillar Myopathy through Mechanosignaling Restoration.

bioRxiv : the preprint server for biology·2026
Same author

WATER reveals heterochrony of molecular programs underlies developmental failure caused by minor spliceosome inhibition.

bioRxiv : the preprint server for biology·2026
Same author

Longitudinal Psychometric Properties of the Myotonic Dystrophy Health Index in a Large Multicenter Cohort of People Living With Myotonic Dystrophy Type 1.

Muscle & nerve·2026
Same author

SHAPE-MaP-Based Assessment of the Structure of Citrus Tristeza Virus Long Non-Coding RNA.

Viruses·2026

Video Experimental Relacionado

Updated: Jul 8, 2026

Tibial Nerve Transection - A Standardized Model for Denervation-induced Skeletal Muscle Atrophy in Mice
10:50

Tibial Nerve Transection - A Standardized Model for Denervation-induced Skeletal Muscle Atrophy in Mice

Published on: November 3, 2013

Un modelo de nocaut muscular ciego para la distrofia miotónica.

Rahul N Kanadia1, Karen A Johnstone, Ami Mankodi

  • 1Department of Molecular Genetics and Microbiology, Powell Gene Therapy Center, Gainesville, FL 32610, USA.

Science (New York, N.Y.)
|December 13, 2003
PubMed
Resumen

La distrofia miotónica (DM) surge de expansiones repetidas. La interrupción del gen Mbnl1 en ratones causó síntomas similares a la DM, apoyando la hipótesis de secuestro de ARN.

Más Videos Relacionados

Modeling Myotonic Dystrophy 1 in C2C12 Myoblast Cells
09:39

Modeling Myotonic Dystrophy 1 in C2C12 Myoblast Cells

Published on: July 29, 2016

Rodent Model of Masseter Volumetric Muscle Loss for Studying Bioengineering Materials
03:46

Rodent Model of Masseter Volumetric Muscle Loss for Studying Bioengineering Materials

Published on: May 31, 2024

Videos de Experimentos Relacionados

Last Updated: Jul 8, 2026

Tibial Nerve Transection - A Standardized Model for Denervation-induced Skeletal Muscle Atrophy in Mice
10:50

Tibial Nerve Transection - A Standardized Model for Denervation-induced Skeletal Muscle Atrophy in Mice

Published on: November 3, 2013

Modeling Myotonic Dystrophy 1 in C2C12 Myoblast Cells
09:39

Modeling Myotonic Dystrophy 1 in C2C12 Myoblast Cells

Published on: July 29, 2016

Rodent Model of Masseter Volumetric Muscle Loss for Studying Bioengineering Materials
03:46

Rodent Model of Masseter Volumetric Muscle Loss for Studying Bioengineering Materials

Published on: May 31, 2024

Área de la Ciencia:

  • Genética La genética.
  • Biología Molecular Biología Molecular
  • Trastornos neuromusculares Trastornos neuromusculares Trastornos neuromusculares Trastornos neuromusculares Trastornos neuromusculares Trastornos neuromusculares Trastornos neuromusculares Trastornos neuromusculares Trastornos neuromusculares Trastornos neuromusculares Trastornos neuromusculares Trastornos neuromusculares Trastornos neuromusculares

Sus antecedentes:

  • La distrofia miotónica (DM) es un trastorno neuromuscular genético.
  • Se caracteriza por expansiones repetidas de microsatélites en genes específicos.
  • Las transcripciones anormales de ARN en pacientes con DM secuestran las proteínas de unión al ARN, interrumpiendo el empalme.

Objetivo del estudio:

  • Para investigar el papel del gen 1 (Mbnl1) en la patogénesis de la DM.
  • Para determinar si la interrupción de Mbnl1 recapitula las características de la enfermedad de DM.
  • Proporcionar evidencia para el mecanismo de secuestro de ARN en DM.

Principales métodos:

  • Disrupción genética de Mbnl1 en un modelo de ratón.
  • Análisis de las anomalías musculares, oculares y de empalme de ARN.
  • Comparación del fenotipo de ratón con deficiencia de Mbnl1 con la DM humana.

Principales resultados:

  • Los ratones que carecían de Mbnl1 funcional exhibieron anormalidades musculares y oculares.
  • Los defectos de empalme de ARN característicos de la DM se observaron en ratones con deficiencia de Mbnl1.
  • Estos hallazgos vinculan directamente Mbnl1 a la patología de la DM.

Conclusiones:

  • El gen Mbnl1 es crucial para el desarrollo normal de los músculos y los ojos.
  • La interrupción de Mbnl1 conduce a un fenotipo de enfermedad que refleja la distrofia miotónica.
  • El secuestro de las proteínas Mbnl por ARN mutantes es un mecanismo clave que impulsa la DM.